Step Pharma CEO Andrew Parker
Step Pharma closes $41M round to take enzyme targeting lead program into early-stage trial for T cell malignancies
The search for better T and B cell therapies have absorbed billions in R&D funds from some of the biggest drugmakers in the world. A …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
